CAS Number138982-67-9
Synonyms5-(2-(4-(1,2-benzisothiazol-3-yl)piperazinyl)ethyl)-6-chlorooxindole Monohydrochloride Monohydrate; cp 88059-1; Ziprasidone; Ziprasidone Hydrochloride Monohydrate; Ziprasidone hydrochloride; MFCD06795476; Ziprasidone (hydrochloride monohydrate)
Molecular FormulaC21H24Cl2N4O2S
Molecular Weight467.41
Purity98%
Boiling Point554.8ºC at 760 mmHg
Melting Point300°C
AppearanceSolid;White to Orange to Green powder to crystal
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 138982-67-9 |
| Catalog No. | 2A-9012996 |
| Chinese Name | 盐酸齐拉西酮 |
| Synonyms | 5-(2-(4-(1,2-benzisothiazol-3-yl)piperazinyl)ethyl)-6-chlorooxindole Monohydrochloride Monohydrate; cp 88059-1; Ziprasidone; Ziprasidone Hydrochloride Monohydrate; Ziprasidone hydrochloride; MFCD06795476; Ziprasidone (hydrochloride monohydrate) |
| Molecular Formula | C21H24Cl2N4O2S |
| Molecular Weight | 467.41 |
| Purity | 98 |
| Boiling Point | 554.8ºC at 760 mmHg |
| Melting Point | 300°C |
| Appearance | Solid;White to Orange to Green powder to crystal |
| Storage Condition | Room temp |
| Application | Ziprasidone (CP88059) is a 5-HT and dopamine receptor antagonist with antipsychotic activity. |
| HTC | 2934999090 |
| PubChem ID | 329751523 |
| MDL Number | MFCD00921885 |
| SMILES | O.Cl.Clc1cc2NC(=O)Cc2cc1CCN3CCN(CC3)c4nsc5ccccc45 |
| InChI | 1S/C21H21ClN4OS.ClH.H2O/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21;;/h1-4,11,13H,5-10,12H2,(H,23,27);1H;1H2 |
| InChI Key | ZCBZSCBNOOIHFP-UHFFFAOYSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| MSDS | msds/12996_1_138982_67_9.pdf |
| Bioactivity | Ziprasidone(CP88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.Target: 5-HT receptor; Dopamine receptorZiprasidone (hydrochloride) is the salt form of ziprasidone, which possesses an in vitro 5-HT2A/dopamine D2 receptor affinity ratio higher than any clinically available antipsychotic agent. In vivo, ziprasidone antagonizes 5-HT2A receptor-induced head twitch with 6-fold higher potency than for blockade of d-amphetamine-induced hyperactivity, a measure of central dopamine D2 receptor antagonism. Ziprasidone also has high affinity for the 5-HT1A, 5-HT1D and 5-HT2C receptor subtypes, which may further enhance its therapeutic potential [1]. Ziprasidone sulfoxide and sulfone were the major metabolites in human serum. The affinities of the sulfoxide and sulfone metabolites for 5-HT2 and D2 receptors are low with respect to ziprasidone, and are thus unlikely to contribute to its antipsychotic effects [2]. Ziprasidone was associated with significant differential adverse effects relative to placebo in BPM, BPD, and schizophrenia with no significant difference in weight gain in all 3 groups. Self-reported somnolence was increased across the 3 conditions. Subjects with BPM were more vulnerable to EPS than those with BPD or schizophrenia [3].Clinical indications: Bipolar I disorder; Bipolar disorder; Mania; SchizophreniaFDA Approved Date: February 2001 Related Catalog Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease References [1]. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. The Journal of Clinical Psychiatry. 2004, 65(2):217-221. [2]. Paul E. Keck, Marcio Versiani, Steven Potkin, et al. Ziprasidone in the Treatment of Acute Bipolar Mania: A Three-Week, Placebo-Controlled, Double-Blind, Randomized Trial. Am J Psychiatry 2003;160:741-748. [3]. Glen L. Stimmel, Mary A. Gutierrez, Vivian Lee. Ziprasidone: An atypical antipsychotic drug for the treatment of schizophrenia. Clinical Therapeutics, 2002, 24(1):21-37. [4]. Anne W Schmidt, Lorraine A Lebel, Harry R Howard Jr. et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. European Journal of Pharmacology. 2001,425(3):197-201. [5]. Ziprasidone Chemical & Physical Properties Boiling Point 554.8ºC at 760 mmHg Melting Point 300°C Molecular Formula C21H24Cl2N4O2S Molecular Weight 467.412 Exact Mass 466.099701 PSA 85.94000 LogP 4.68760 Vapour Pressure 2.38E-12mmHg at 25°C InChIKey ZCBZSCBNOOIHFP-UHFFFAOYSA-N SMILES Cl.O.O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1 Storage condition Room temp |
| Use of | Properties Articles28 Name ziprasidone hydrochloride hydrate Synonym More Synonyms Ziprasidone Hydrochloride Monohydrate Biological Activity Related Catalog Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease References [1]. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. The Journal of Clinical Psychiatry. 2004, 65(2):217-221. [2]. Paul E. Keck, Marcio Versiani, Steven Potkin, et al. Ziprasidone in the Treatment of Acute Bipolar Mania: A Three-Week, Placebo-Controlled, Double-Blind, Randomized Trial. Am J Psychiatry 2003;160:741-748. [3]. Glen L. Stimmel, Mary A. Gutierrez, Vivian Lee. Ziprasidone: An atypical antipsychotic drug for the treatment of schizophrenia. Clinical Therapeutics, 2002, 24(1):21-37. [4]. Anne W Schmidt, Lorraine A Lebel, Harry R Howard Jr. et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. European Journal of Pharmacology. 2001,425(3):197-201. [5]. Ziprasidone Chemical & Physical Properties Exact Mass 466.099701 PSA 85.94000 LogP 4.68760 InChIKey ZCBZSCBNOOIHFP-UHFFFAOYSA-N Storage condition Room temp |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information United Nations classification: inconsistent with United Nations classification standards UN number: not specified |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Voriconazole | 137234-62-9 | 2A-9012956 |
| Warfarin sodium | 129-06-6 | 2A-9012957 |
| Zafirlukast | 107753-78-6 | 2A-9012979 |
| Zaleplon | 151319-34-5 | 2A-9012980 |
| Zidovudine | 30516-87-1 | 2A-9012988 |
| Zolpidem tartrate | 99294-93-6 | 2A-9013004 |
| Alendronate Sodium (Fosamax) | 121268-17-5 | 2A-9013617 |
| Formoterol fumarate | 43229-80-7 | 2A-9014472 |
| Lithium carbonate | 554-13-2 | 2A-9014763 |
| Hydrocortisone acetate | 50-03-3 | 2A-9016535 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS